Modulation of nonspecific binding in ultrafiltration protein binding studies. 2003

Kyoung-Jin Lee, and Rachel Mower, and Tom Hollenbeck, and Jesus Castelo, and Nikole Johnson, and Perry Gordon, and Patrick J Sinko, and Kevin Holme, and Yong-Hee Lee
DMPK, Lion Bioscience, San Diego, California 92121, USA.

OBJECTIVE The aim of this study was to reduce or prevent nonspecific binding (NSB) of compounds to ultrafiltration (UF) protein binding (PB) testing units. METHODS UF units (regenerated cellulose, MWCO 10K) were used for PB and NSB measurements with or without pretreatment with 5% tween 80 (TW 80) or 5% benzalkonium chloride (BAK) on the filter membrane. Dosing solutions (10 microM) in human serum and pH 7.4 phosphate-buffered saline were centrifuged at 3,000 g and room temperature after 1-h incubation in UF testing units. In parallel, a 96-well equilibrium dialyzer was used for PB and NSB measurements in equilibrium dialysis (ED) at 37 degrees C for 4 h. Samples of UF and ED were analyzed by LC/MS or LSC. RESULTS Severe NSB was observed for etoposide, hydrocortisone, propranolol, and vinblastine in UF. In contrast, TW 80 or BAK pre-treatment on the filter membrane decreased the NSB from 87-95% to 13-64% without causing a significant change in membrane integrity. When NSB was below 50% as a result of pretreating agents, PB data of marker compounds were comparable to those of ED. CONCLUSIONS The pretreated membrane with TW 80 or BAK showed significantly less NSB for compounds that had a tendency toward high membrane binding. A modified UF method with pretreatment improved the performance of UF and was able to produce comparable PB results to ED.

UI MeSH Term Description Entries
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014462 Ultrafiltration The separation of particles from a suspension by passage through a filter with very fine pores. In ultrafiltration the separation is accomplished by convective transport; in DIALYSIS separation relies instead upon differential diffusion. Ultrafiltration occurs naturally and is a laboratory procedure. Artificial ultrafiltration of the blood is referred to as HEMOFILTRATION or HEMODIAFILTRATION (if combined with HEMODIALYSIS).

Related Publications

Kyoung-Jin Lee, and Rachel Mower, and Tom Hollenbeck, and Jesus Castelo, and Nikole Johnson, and Perry Gordon, and Patrick J Sinko, and Kevin Holme, and Yong-Hee Lee
October 1961, The Journal of endocrinology,
Kyoung-Jin Lee, and Rachel Mower, and Tom Hollenbeck, and Jesus Castelo, and Nikole Johnson, and Perry Gordon, and Patrick J Sinko, and Kevin Holme, and Yong-Hee Lee
December 1984, The Journal of pharmacy and pharmacology,
Kyoung-Jin Lee, and Rachel Mower, and Tom Hollenbeck, and Jesus Castelo, and Nikole Johnson, and Perry Gordon, and Patrick J Sinko, and Kevin Holme, and Yong-Hee Lee
December 1986, Research communications in chemical pathology and pharmacology,
Kyoung-Jin Lee, and Rachel Mower, and Tom Hollenbeck, and Jesus Castelo, and Nikole Johnson, and Perry Gordon, and Patrick J Sinko, and Kevin Holme, and Yong-Hee Lee
January 1985, Methods in enzymology,
Kyoung-Jin Lee, and Rachel Mower, and Tom Hollenbeck, and Jesus Castelo, and Nikole Johnson, and Perry Gordon, and Patrick J Sinko, and Kevin Holme, and Yong-Hee Lee
June 1971, European journal of biochemistry,
Kyoung-Jin Lee, and Rachel Mower, and Tom Hollenbeck, and Jesus Castelo, and Nikole Johnson, and Perry Gordon, and Patrick J Sinko, and Kevin Holme, and Yong-Hee Lee
February 1981, Journal of pharmaceutical sciences,
Kyoung-Jin Lee, and Rachel Mower, and Tom Hollenbeck, and Jesus Castelo, and Nikole Johnson, and Perry Gordon, and Patrick J Sinko, and Kevin Holme, and Yong-Hee Lee
June 1985, Archiv der Pharmazie,
Kyoung-Jin Lee, and Rachel Mower, and Tom Hollenbeck, and Jesus Castelo, and Nikole Johnson, and Perry Gordon, and Patrick J Sinko, and Kevin Holme, and Yong-Hee Lee
June 1977, British journal of clinical pharmacology,
Kyoung-Jin Lee, and Rachel Mower, and Tom Hollenbeck, and Jesus Castelo, and Nikole Johnson, and Perry Gordon, and Patrick J Sinko, and Kevin Holme, and Yong-Hee Lee
April 1988, Drug intelligence & clinical pharmacy,
Kyoung-Jin Lee, and Rachel Mower, and Tom Hollenbeck, and Jesus Castelo, and Nikole Johnson, and Perry Gordon, and Patrick J Sinko, and Kevin Holme, and Yong-Hee Lee
October 1981, Archiv der Pharmazie,
Copied contents to your clipboard!